论文部分内容阅读
观察膜肺（ECMO）过程对羊头孢拉定药代动力学的影响。通过在ECMO 前和ECMO 中对8 只绵羊静注头孢拉定，观察药物在动物体内的分布和代谢情况。与ECMO 前自身对照比较，ECMO 中药动力参数表现为清除相半衰期（T 1/2 b）延长（38.1 6.1min vs 69.8 17.0min P<0.01）总表观分布容积（V d） 增大（0.30 0.12L/kg vs 0.46 0.18L/kg P<0.01），而清除率（Cl）等其它参数无明显改变。体外循环中膜氧合器前后头孢拉定血药浓度测定结果无任何差异。（1）ECMO 治疗过程并不影响药物清除率，清除相半衰期延长可能来源于体外循环所致的总表观分布容积增大。（2）膜氧合器本身对药物并无清除作用。
The effects of membrane membrane lung (ECMO) on the pharmacokinetics of cephradine were observed. Cefradine was administered intravenously to eight sheep in pre-ECMO and ECMO to observe the distribution and metabolism of the drug in the animal. Compared with the former ECMO self-control, the dynamic parameters of ECMO showed an increase in the total apparent volume of distribution (V d) (0.30 0.12, P <0.01) when the phase half-life (T 1/2 b) L / kg vs 0.46 0.18L / kg P <0.01), while other parameters such as clearance (Cl) did not change significantly. Cardiopulmonary bypass membrane oxygenator before and after cefradine determination of plasma concentrations without any difference. (1) ECMO treatment does not affect the drug clearance, and the half-life of the clear phase may be derived from the increase of the total apparent volume of distribution due to cardiopulmonary bypass. (2) Membrane oxygenator itself has no scavenging effect on the drug.